Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective

CONCLUSIONS: TIS for treating r/r DLBCL patients who have failed ≥2 lines of systemic therapies, is likely to be cost effective with limited budget impact.PMID:33904359 | DOI:10.1080/13696998.2021.1922066

Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Xiao Jun Wang Yi-Ho Wang Shing Chau Tony Li Christina Gkitzia Soon Thye Lim Liang Piu Koh Francesca Lorraine Wei Inng Lim William Ying Khee Hwang Source Type: research